Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+metastatic breast cancer: an analysis of the SONABRE registry

被引：3

作者：

Geurts, Sandra M. E. ^{[1
]}

Ibragimova, Khava I. E. ^{[1
]}

Ding, Nan ^{[1
]}

Meegdes, Marissa ^{[1
]}

Erdkamp, Frans ^{[2
]}

Heijns, Joan B. ^{[3
]}

Tol, Jolien ^{[4
]}

Vriens, Birgit E. P. J. ^{[5
]}

Dercksen, Marcus W. ^{[6
]}

Aaldering, Kirsten N. A. ^{[7
]}

Pepels, Manon J. A. E. ^{[8
]}

van de Winkel, Linda ^{[9
]}

Peters, Natascha A. J. B. ^{[10
]}

van de Wouw, Agnes J. ^{[11
]}

Maaskant, Sabrina A. J. G. ^{[12
]}

Teeuwen-Dedroog, Nathalie J. A. ^{[1
]}

van Nijnatten, Thiemo J. A. ^{[13
]}

de Boer, Maaike ^{[1
]}

Tjan-Heijnen, Vivianne C. G. ^{[1
]}

机构：

[1] Maastricht Univ, GROW Sch Oncol & Reprod, Med Ctr, Dept Med Oncol, POB 5800, NL-6202 AZ Maastricht, Netherlands

[2] Zuyderland Med Ctr, Dept Internal Med, Geleen, Netherlands

[3] Amphia, Dept Med Oncol, Breda, Netherlands

[4] Jeroen Bosch Hosp, Dept Med Oncol, Den Bosch, Netherlands

[5] Catharina Hosp, Dept Internal Med, Eindhoven, Netherlands

[6] Maxima Med Ctr, Dept Med Oncol, Eindhoven, Netherlands

[7] Laurentius Hosp, Dept Internal Med, Roermond, Netherlands

[8] Elkerliek Hosp, Dept Internal Med, Helmond, Netherlands

[9] St Anna Hosp, Dept Internal Med, Geldrop, Netherlands

[10] Sint Jans Gasthuis Hosp, Dept Internal Med, Weert, Netherlands

[11] Viecuri Med Ctr, Dept Internal Med, Venlo, Netherlands

[12] Maxima Med Ctr, Dept Surg, Eindhoven, Netherlands

[13] Maastricht Univ, Dept Radiol & Nucl Med, Med Ctr, GROW, Maastricht, Netherlands

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2024年 / 205卷 / 02期

关键词：

Breast neoplasms; ERBB2; protein; human; Neoplasm metastasis; Pertuzumab; Registries; Survival; STAGE IV; DOUBLE-BLIND; TRASTUZUMAB; PERTUZUMAB; DOCETAXEL; CLEOPATRA; THERAPY;

D O I：

10.1007/s10549-023-07235-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PurposeThe aim was to determine whether the real-world first-line progression-free survival (PFS) of patients diagnosed with de novo human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer (ABC) has improved since the introduction of pertuzumab in 2013. In addition to PFS, we aimed to determine differences in overall survival (OS) and the use of systemic and locoregional therapies.MethodsIncluded were patients systemically treated for de novo HER2+ ABC in ten hospitals in 2008-2017 from the SONABRE Registry (NCT-03577197). First-line PFS and OS in 2013-2017 versus 2008-2012 was determined using Kaplan-Meier analyses and multivariable Cox proportional hazards modelling. First-given systemic therapy and the use of locoregional therapy within the first year following diagnosis were determined per period of diagnosis.ResultsMedian and five-year PFS were 26.6 months and 24% in 2013-2017 (n = 85) versus 14.5 months and 10% in 2008-2012 (n = 81) (adjusted HR = 0.65, 95%CI:0.45-0.94). Median and five-year OS were 61.2 months and 51% in 2013-2017 versus 26.1 months and 28% in 2008-2012 (adjusted HR = 0.55, 95%CI:0.37-0.81). Of patients diagnosed in 2013-2017 versus 2008-2012, 84% versus 60% received HER2-targeted therapy and 59% versus 0% pertuzumab-based therapy as first-given therapy. Respectively, 27% and 23% of patients underwent locoregional breast surgery, and 6% and 7% surgery of a metastatic site during the first year following diagnosis.ConclusionThe prognosis of patients with de novo HER2 + ABC has improved considerably. Since 2013 one in four patients were alive and free from progression on first-given therapy for at least five years.

引用

页码：287 / 302

页数：16

共 30 条

[1] Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial [J].

Badwe, Rajendra ;

Hawaldar, Rohini ;

Nair, Nita ;

Kaushik, Rucha ;

Parmar, Vani ;

Siddique, Shabina ;

Budrukkar, Ashwini ;

Mittra, Indraneel ;

Gupta, Sudeep .

LANCET ONCOLOGY, 2015, 16 (13) :1380-1388

[2] 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [J].

Cardoso, F. ;

Paluch-Shimon, S. ;

Senkus, E. ;

Curigliano, G. ;

Aapro, M. S. ;

Andre, F. ;

Barrios, C. H. ;

Bergh, J. ;

Bhattacharyya, G. S. ;

Biganzoli, L. ;

Boyle, F. ;

Cardoso, M-J ;

Carey, L. A. ;

Cortes, J. ;

El Saghir, N. S. ;

Elzayat, M. ;

Eniu, A. ;

Fallowfield, L. ;

Francis, P. A. ;

Gelmon, K. ;

Gligorov, J. ;

Haidinger, R. ;

Harbeck, N. ;

Hu, X. ;

Kaufman, B. ;

Kaur, R. ;

Kiely, B. E. ;

Kim, S-B ;

Lin, N. U. ;

Mertz, S. A. ;

Neciosup, S. ;

Offersen, B., V ;

Ohno, S. ;

Pagani, O. ;

Prat, A. ;

Penault-Llorca, F. ;

Rugo, H. S. ;

Sledge, G. W. ;

Thomssen, C. ;

Vorobiof, D. A. ;

Wiseman, T. ;

Xu, B. ;

Norton, L. ;

Costa, A. ;

Winer, E. P. .

ANNALS OF ONCOLOGY, 2020, 31 (12) :1623-1649

[3] ESMO Guidance for Reporting Oncology real-World evidence (GROW) [J].

Castelo-Branco, L. ;

Pellat, A. ;

Martins-Branco, D. ;

Valachis, A. ;

Derksen, J. W. G. ;

Suijkerbuijk, K. P. M. ;

Dafni, U. ;

Dellaporta, T. ;

Vogel, A. ;

Prelaj, A. ;

Groenwold, R. H. H. ;

Martins, H. ;

Stahel, R. ;

Bliss, J. ;

Kather, J. ;

Ribelles, N. ;

Perrone, F. ;

Hall, P. S. ;

Dienstmann, R. ;

Booth, C. M. ;

Pentheroudakis, G. ;

Delaloge, S. ;

Koopman, M. .

ANNALS OF ONCOLOGY, 2023, 34 (12) :1097-1112

[4] Epidemiology of De Novo Metastatic Breast Cancer [J].

Daily, Karen ;

Douglas, Emily ;

Romitti, Paul A. ;

Thomas, Alexandra .

CLINICAL BREAST CANCER, 2021, 21 (04) :302-308

[5] Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed [J].

den Brok, Wendie D. ;

Speers, Caroline H. ;

Gondara, Lovedeep ;

Baxter, Emily ;

Tyldesley, Scott K. ;

Lohrisch, Caroline A. .

BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (03) :549-556

[6] Impact of Breast Surgery in Primary Metastasized Breast Cancer Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial [J].

Fitzal, Florian ;

Bjelic-Radisic, Vesna ;

Knauer, Michael ;

Steger, Gunther ;

Hubalek, Michael ;

Balic, Marija ;

Singer, Christian ;

Bartsch, Rupert ;

Schrenk, Peter ;

Soelkner, Lidija ;

Greil, Richard ;

Gnant, Michael .

ANNALS OF SURGERY, 2019, 269 (06) :1163-1169

[7] A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study [J].

Gamucci, Teresa ;

Pizzuti, Laura ;

Natoli, Clara ;

Mentuccia, Lucia ;

Sperduti, Isabella ;

Barba, Maddalena ;

Sergi, Domenico ;

Iezzi, Laura ;

Maugeri-Sacca, Marcello ;

Vaccaro, Angela ;

Magnolfi, Emanuela ;

Gelibter, Alain ;

Barchiesi, Giacomo ;

Magri, Valentina ;

D'Onofrio, Loretta ;

Cassano, Alessandra ;

Rossi, Ernesto ;

Botticelli, Andrea ;

Moscetti, Luca ;

Omarini, Claudia ;

Fabbri, Maria Agnese ;

Scinto, Angelo Fedele ;

Corsi, Domenico ;

Carbognin, Luisa ;

Mazzotta, Marco ;

Bria, Emilio ;

Foglietta, Jennifer ;

Samaritani, Riccardo ;

Garufi, Carlo ;

Mariani, Luciano ;

Barni, Sandro ;

Mirabelli, Rosanna ;

Sarmiento, Roberta ;

Graziano, Vincenzo ;

Santini, Daniele ;

Marchetti, Paolo ;

Tonini, Giuseppe ;

Di Lauro, Luigi ;

Sanguineti, Giuseppe ;

Paoletti, Giancarlo ;

Tomao, Silverio ;

De Maria, Ruggero ;

Veltri, Enzo ;

Paris, Ida ;

Giotta, Francesco ;

Latorre, Agnese ;

Giordano, Antonio ;

Ciliberto, Gennaro ;

Vici, Patrizia .

CANCER BIOLOGY & THERAPY, 2019, 20 (02) :192-200

[8] ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer [J].

Gennari, A. ;

Andre, F. ;

Barrios, C. H. ;

Cortes, J. ;

de Azambuja, E. ;

DeMichele, A. ;

Dent, R. ;

Fenlon, D. ;

Gligorov, J. ;

Hurvitz, S. A. ;

Im, S. -a. ;

Krug, D. ;

Kunz, W. G. ;

Loi, S. ;

Penault-Llorca, F. ;

Ricke, J. ;

Robson, M. ;

Rugo, H. S. ;

Saura, C. ;

Schmid, P. ;

Singer, C. F. ;

Spanic, T. ;

Tolaney, S. M. ;

Turner, N. C. ;

Curigliano, G. ;

Loibl, S. ;

Paluch-Shimon, S. ;

Harbeck, N. .

ANNALS OF ONCOLOGY, 2021, 32 (12) :1475-1495

[9] Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis [J].

Gera, Ritika ;

Chehade, Hiba E. L. Hage ;

Wazir, Umar ;

Tayeh, Salim ;

Kasem, Abdul ;

Mokbel, Kefah .

SCIENTIFIC REPORTS, 2020, 10 (01)

[10] Systemic Therapy for Advanced Human 3 Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update [J].

Giordano, Sharon H. ;

Temin, Sarah ;

Chandarlapaty, Sarat ;

Crews, Jennie R. ;

Kirshner, Jeffrey J. ;

Krop, Ian E. ;

Lin, Nancy U. ;

Patt, Debra A. ;

Perlmutter, Jane ;

Ramakrishna, Naren ;

Davidson, Nancy E. ;

Franzoi, Maria Alice B. ;

Anders, Carey K. ;

Ikawa, Aki .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (23) :2612-+

← 1 2 3 →